tradingkey.logo
tradingkey.logo
검색

Biontech SE

BNTX
관심 목록에 추가
91.220USD
+1.220+1.36%
종가 06/26, 16:00ET시세는 15분 지연됩니다
23.07B시가총액
손실P/E TTM

자세한 내용은 Biontech SE 회사

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SE 정보

종목 코드 BNTX
회사 이름Biontech SE
상장일Oct 10, 2019
CEOSahin (Ugur)
직원 수6772
유형Depository Receipt
회계 연도 종료Oct 10
주소An der Goldgrube 12
도시MAINZ
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Germany
우편 번호55131
전화4949613190840
웹사이트https://www.biontech.com/
종목 코드 BNTX
상장일Oct 10, 2019
CEOSahin (Ugur)

Biontech SE의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--

자주 묻는 질문

Biontech SE의 상위 5대 주주는 누구인가요?

Biontech SE의 상위 5대 주주는 다음과 같습니다: Dr. Sierk Poetting, Ph.D.

Biontech SE(BNTX)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Biontech SE의 주식을 보유한 기관은 총 802곳이며, 이들이 보유한 주식의 총 가치는 약 51.86M로 전체 발행 주식의 20.51%를 차지합니다. 이는 2025Q4 대비 -1292358.00 증가한 수치입니다.

Biontech SE의 최대 수익원은 무엇인가요?

2026Q1 기준, Biontech SE의 Collaboration Revenue 부문이 가장 높은 매출을 기록했으며, 금액은 84.43M로 전체 매출의 77.75%를 차지했습니다.
KeyAI